THE EFFECT OF IL28B POLYMORPHISMS ON VIROLOGIC RESPONSE TO TREATMENT WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) ADDED TO ABT-450/RITONAVIR (ABT-450/R), ABT-333, OR ABT-072

被引：5
|
作者：
Gaultier, I. [1 ]
Cohen, D. E. [1 ]
Bhathena, A. [1 ]
Idler, K. [1 ]
Larsen, L. M. [1 ]
Podsadecki, T. [1 ]
Bernstein, B. [1 ]
机构：
[1] Abbott, Abbott Pk, IL USA
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)61329-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1327
引用
收藏
页码：S523 / S523
页数：1
相关论文
共 38 条
  • [21] PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treatment-Experienced Patients
    Andreone, Pietro
    Colombo, Massimo
    Enejosa, Jeffrey V.
    Koksal, Iftihar
    Ferenci, Peter
    Maieron, Andreas
    Muellhaupt, Beat
    Horsmans, Yves
    Weiland, Ola
    Reesink, Henk W.
    Rodrigues, Lino, Jr.
    Hu, Yiran B.
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S159 - S159
  • [22] Sustained Virologic Response 12 Weeks Post-Treatment With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With Ribavirin (SAPPHIRE I and II) is Independent of Patient Subgroups
    Brunetto, Maurizia Rossana
    Makara, Mihaly
    Hinrichsen, Holger
    Hanson, John
    Bennett, Michael
    Lawitz, Eric
    Xiong, Junyuan
    Coakley, Eoin
    Baykal, Tolga
    Neff, Guy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S133 - S133
  • [23] Pearl-IV: a 12-Week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves Svr12 Rates ≥90% in Treatment-Naive Adults Infected With Hepatitis C Virus Genotype 1A
    Bernstein, David
    Lalezari, Jacob
    Luo, Yan
    Box, Terry D.
    Younes, Ziad H.
    Green, Sinikka
    Bhandari, Bai R.
    Sepe, Thomas
    Cooper, Curtis
    Tam, Edward
    Tsai, Naoky
    Hassanein, Tarek
    Xie, Wangang
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S977 - S978
  • [24] Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naive Patients and Prior Null Responders
    Lawitz, Eric
    Hezode, Christophe
    Varunok, Peter
    Thuluvath, Paul J.
    Baykal, Tolga
    Kapoor, Mudra
    Lovell, Sandra S.
    Wang, Tianli
    Pilot-Matias, Tami
    Vilchez, Regis A.
    Bernstein, Barry
    HEPATOLOGY, 2013, 58 : 244A - 244A
  • [25] A 12-Week Interferon-free Treatment Regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naive Patients and 93% in Prior Null Responders with HCV Genotype1 Infection
    Kowdley, Kris V.
    Lawitz, Eric
    Poordad, Fred
    Cohen, Daniel E.
    Nelson, David R.
    Zeuzem, Stefan
    Everson, Gregory T.
    Kwo, Paul Y.
    Foster, Graham R.
    Sulkowski, Mark S.
    Xie, Wangang
    Pilot-Matias, Tami
    Liossis, George
    Larsen, Lois M.
    Khatri, Amit
    Podsadecki, Thomas J.
    Bernstein, Barry
    HEPATOLOGY, 2012, 56 (06) : 1515 - 1516
  • [26] IN VITRO COMBINATORY EFFECT OF HCV NS3/4A PROTEASE INHIBITOR ABT-450, NS5A INHIBITOR ABT-267, AND NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR ABT-333
    Pilot-Matias, T.
    Koev, G.
    Krishnan, P.
    Beyer, J.
    Reisch, T.
    Mondal, R.
    Lu, L.
    Middleton, T.
    Maring, C.
    Kati, W.
    Collins, C.
    Molla, A.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S338 - S338
  • [27] ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
    Andreone, Pietro
    Colombo, Massimo G.
    Enejosa, Jeffrey V.
    Koksal, Iftihar
    Ferenci, Peter
    Maieron, Andreas
    Muellhaupt, Beat
    Horsmans, Yves
    Weiland, Ola
    Reesink, Henk W.
    Rodrigues, Lino, Jr.
    Hu, Yiran B.
    Podsadecki, Thomas
    Bernstein, Barry
    GASTROENTEROLOGY, 2014, 147 (02) : 359 - +
  • [28] TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)
    Kowdley, Kris V.
    Poordad, Fred
    Trinh, Roger
    Hezode, Christophe
    Zeuzem, Stefan
    Agarwal, Kosh
    Shiffman, Mitchell L.
    Wedemeyer, Heiner
    Berg, Thomas
    Yoshida, Eric M.
    Forns, Xavier
    Lovell, Sandra S.
    DaSilva-Tillmann, Barbara
    Campbell, Andrew L.
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S903 - S903
  • [29] RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION
    Hezode, C.
    Marcellin, P.
    Pol, S.
    Hassanein, T.
    Fleischer-Stepniewska, K.
    Baykal, T.
    Wang, T.
    Lovell, S. S.
    Pilot-Matias, T.
    Vilchez, R. A.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S24 - S24
  • [30] Results From the Phase 2 PEARL-I Study: Interferon-Free Regimens of ABT-450/r + ABT-267 With or Without Ribavirin in Patients With HCV Genotype 4 Infection
    Hezode, Christophe
    Marcellin, Patrick
    Pol, Stanislas
    Hassanein, Tarek
    Fleischer-Stepniewska, Katarzyna
    Baykal, Tolga
    Wang, Tianli
    Lovell, Sandra
    Pilot-Matias, Tami
    Vilchez, Regis
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S131 - S131
1234